A recent study reveals that patients who stop using new GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass far faster than those who halt traditional lifestyle plans.
Published data in a prominent health publication demonstrates that while obese individuals frequently drop about a fifth of their total mass while undergoing treatment, the weight is regained at an average rate of 0.8 kg per month upon discontinuation.
"Individuals buying such drugs must be informed of the danger of rapid weight regain when the therapy ends," warns lead investigator Dr. Susan Jebb.
This pace of regain means a reversion to original weight within about one and a half years.
Analyzing Approaches
The analysis, which looked at 37 of studies involving over 9,000 of patients, compared the effects of these new drugs with conventional dieting.
Scientists point out that people who shed pounds through diet and exercise typically have a more gradual creep back—around 100 grams monthly—after stopping.
Understanding the Quick Rebound
Doctors suggest the mechanism of the jabs explains the accelerated weight return.
These medications copy a body's own chemical called GLP-1, which controls feelings of fullness.
"Artificially providing GLP-1 concentrations far above than the body's typical production may cause the system to produce less of its endogenous hormone, and could diminish sensitivity to its actions," noted Dr. Adam Collins, a dietetics expert.
"Discontinuation of this medication leads to appetite is no longer kept in check, making binge eating far more likely."
An Ongoing Disease?
The NHS suggest the jabs for individuals with obesity-related health risks, accompanied by prescribed lifestyle changes.
Many experts contend that, given the significant potential of relapse, the therapy might need to be long-term.
This perspective is reinforced by drug manufacturers, who note that the results "underscore the persistent nature of obesity," similar to managing conditions like high blood pressure.
Patient Experiences
Individuals who have come off the medication describe a powerful resurgence of hunger.
"It was like a switch flipping and I was suddenly extremely hungry," described an individual.
The struggle is compounded if users have not developed lasting lifestyle or habit changes during therapy.
Significant Interest
Recent estimates suggest that millions of adults in the UK have tried these injections in the last 12 months, with desire continuing to grow.
- Use is more common among women than males.
- The 40s and 50s age group shows the highest level of interest.
- A large proportion access the medications through private prescriptions rather than the NHS.
In conclusion, experts emphasize that while the jabs are effective tools for shedding pounds, they are not a standalone fix and lasting health benefits relies on combined behavioural management.
